SLS vs LEGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SLS · Sellas Life Sciences$13.66 ▼ 8.08%
LEGN · Legend Biotech$15.25 ▼ 5.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SLS +781.3%
- LEGN -43.8%
Head to head
| Metric | SLS | LEGN |
|---|---|---|
| Price | $13.66 | $15.25 |
| Change today | ▼ 8.08% | ▼ 5.28% |
| Market cap | $2.78B | $2.96B |
| Return, 3 months | -4.7% | -27.2% |
| Return, year to date | +262.3% | -29.9% |
| Return, 1 year | +792.8% | -45.9% |
| P/E (TTM) | – | – |
| P/B | 21.1 | 2.3 |
| P/E percentile vs own 5y | 8th | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +32.0% |
| Net profit growth (YoY) | -48.6% | +230.6% |
| Gross margin | – | 57.0% |
| Operating margin | – | 2.6% |
| Net margin | – | 0.0% |
| Return on equity | -40.3% | 0.0% |
| Analyst target vs. price | +119.6% | +174.8% |
| Analyst buy share | 100% | 60% |
| RSI (14) | 56 | 31 |
| 30-day volatility | 304.0% | 82.6% |
| Max drawdown, 1 year | -51.7% | -58.0% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LEGN is the largest of the group by market value.
- SLS has returned the most over the past year.
- LEGN has been the calmest stock over the last 30 days.